Rocha-Lima Caio M, Raez Luis E
P T. 2009 Oct;34(10):554-64.
Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the epidermal growth factor receptor. Randomized, controlled clinical studies have demonstrated that erlotinib significantly improved survival in patients with previously treated non-small-cell lung cancer and, in combination with chemotherapy, in patients with untreated pancreatic cancer. In this article, we describe the clinical evidence and value of erlotinib as a therapy for non-small-cell lung cancer and pancreatic cancer and discuss ongoing clinical studies to optimize its use in various settings and to identify appropriate patient populations.
厄洛替尼（特罗凯）是一种口服的小分子抗癌药物，可抑制表皮生长因子受体。随机对照临床研究表明，厄洛替尼可显著提高既往接受过治疗的非小细胞肺癌患者的生存率，与化疗联合使用时，可提高未接受过治疗的胰腺癌患者的生存率。在本文中，我们描述了厄洛替尼作为非小细胞肺癌和胰腺癌治疗药物的临床证据和价值，并讨论了正在进行的临床研究，以优化其在各种情况下的使用，并确定合适的患者群体。
